stockrowXeris Biopharma Holdings, Inc.
XERS Healthcare Drug Manufacturers Specialty & Generic
Xeris Biopharma Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $291.8 million, up 43.7% from fiscal 2024.
- Revenue
- +44.2%
- EPS
- +1,479.0%
- Free cash flow
- +93.2%
- Total debt
- −13.6%
Quarter to September 2026, against a year earlier
Follow XERS
Alert me
Xeris Biopharma Holdings, Inc. (XERS) Return on assets
Xeris Biopharma Holdings, Inc.'s return on assets over the twelve months to 30 September 2026 was −1.64%, down 1.8 percentage points from fiscal 2025 (0.16%). Over the past ten years it has ranged from −109.7% (fiscal 2019) to 0.16% (fiscal 2025) — the current reading is the highest in ten years. That is in line with the Drug Manufacturers Specialty & Generic industry median of −1.67% and above the Healthcare sector median of −29.5%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 0.16% | 17.15 |
| FY2024 | −17.0% | 1.67 |
| FY2023 | −18.7% | 10.52 |
| FY2022 | −29.2% | 23.77 |
| FY2021 | −53.0% | 15.03 |
| FY2020 | −68.0% | 41.69 |
| FY2019 | −109.7% | (36.86) |
| FY2018 | −72.8% | (5.18) |
| FY2017 | −67.6% | (33.99) |
| FY2016 | −33.6% | — |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| PBH Prestige Consumer Healthcare Inc. compare | 3.80% |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | 0.00% |
| RGC Regencell Bioscience Holdings Limited compare | 0.00% |
| ALVO Alvotech compare | 0.00% |
| XERS Xeris Biopharma Holdings, Inc. | −1.64% |
| TRLV Trulieve Cannabis Corp. compare | −17.6% |
| PRGO Perrigo Company plc compare | −20.2% |
| AMLX Amylyx Pharmaceuticals, Inc. compare | −66.3% |
| BCRX BioCryst Pharmaceuticals, Inc. compare | −69.3% |
| Drug Manufacturers Specialty & Generic industry median | −1.67% |
| Healthcare sector median | −29.5% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on XERS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement